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Time to Diagnosis of Lung Cancer
Technical and Pyschological Factors that Slow Down Diagnostic
and Treatment Timelines
Jean Louis Pujol, MD, PhD, and Xavier Quantin, MD, PhD
It is now clearly established that prognosis of non-small cell lung cancer mainly dependson the disease stage at time of diagnosis.1 Screening programs,2 early detection of lung
cancer, and implementation of new health systems toward shorter diagnosis timelines3,4
are sharing in common a nearly similar end point, bringing lung cancers to curative
treatment by detecting them as earlier as possible. In this issue of the Journal of Thoracic
Oncology, Aukema et al.3 have reported a prospective study describing feasibility of a
“Fast track one-day lung schedule.” This pilot study was designed in an attempt at
determining in 1 day, whether suspicious abnormalities (SAs) on standard chest radiog-
raphies could be diagnosed as malignancy or not. Patients underwent both 18F-fluorode-
oxyglucose positron emission tomography and bronchoscopy in a single day; then, a final
report of the conclusions was presented to the patient. Delays in diagnosis of lung cancer
are potentially a loss of chance for curative treatment; furthermore, they increase anxiety
in patients in whom the SA has been detected. This original attempt at reducing these wait
times merit analysis under the dual points of methodological and psychologic aspects. In
this brief editorial, we also like to put this article into perspective with other studies on
diagnosis of SA that have been recently published in the Journal of Thoracic Oncology.4,5
The length of time of asymptomatic lung cancer is probably the main factor for
delayed diagnosis and a loss of chance for curative treatment. Time passing from the
beginning of bronchial carcinogenesis until the onset of symptoms or the serendipitous
discovery of a radiographic SA is likely to be counted in years rather than in months. A
recent review on natural history (i.e., patient survival in the absence of any active
treatment) suggested that the estimated volume-doubling time of incidentally detected
abnormalities on computed tomography scan, such as ground glass opacities, might be
longer than 400 days.6 Screening programs are designed in an attempt at reducing this
preclinical period without adding morbidity to subjects presenting with benign diseases.
Once symptoms have occurred, rapid diagnosis is less important in determining treatment
with curative intent than detecting lung cancer during the asymptomatic period.
Time to diagnosis has been shown to vary widely, and this is a complex and
multidimensional variable.7 A long time from suspicion until diagnosis reduces the chance
for a patient to undergo treatment with curative intent, particularly in the case of lung
tumor with short doubling time such as small cell lung cancers. Waiting time to diagnosis
is from the patient’s point of view, a period of uncertainty that clearly feeds fears and
anxiety. Arbitrarily, one can separate this waiting time to diagnosis in two different
periods: first, from symptoms until detection of SA and second from suspicion (SA) until
a complete diagnosis including histology, characteristics of the disease, and patient
comorbid conditions; In other words, time from detection until treatment decision.
There are numerous factors that influence both times from symptoms until detection
and from suspicion until diagnosis. During the first period, patient and physician could
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unintentionally extend the length from symptom onset until
suspicion. Patients are frequently reluctant to frankly speak
about respiratory symptoms when they are smokers, a behav-
ior clearly related to the feelings of shame and guilty.8 This
behavior is a consequence of general supposition that lung
cancer is a self-inflicted disease, and this is a stigma com-
monly felt by patients. General practitioners know that lung
cancer has one of the poorer prognoses of any human malig-
nancies and that might unintentionally limit proposals a
patient presenting with symptoms adequate investigations. In
addition, symptoms of lung cancer sometimes divert investi-
gations from the thorax. This is the case of Pancoast syn-
drome frequently presenting as shoulder pains that could refer
the patient for months to the rheumatologist.9
During the period lasting from suspicion (i.e., detection
of a SA on chest radiography or computed tomography scan)
until diagnosis, the main factors that slow down the diagnosis
process are access to complex investigations and delays in
consultation with medical oncologists or surgeons. In a recent
retrospective review of 540 patients diagnosed with non-
small cell lung cancer in different health institutions of Nova
Scotia, Canada, during the year 2005, elapsed times have
been measured in different care intervals.7 As a marker of
timelines in the spectrum of lung cancer management, the
median waiting time from detection until adjuvant chemo-
therapy has been evaluated as 141 days. The most important
finding of this study was that elapsed times in lung cancer
care greatly varied from one case to another depending on
differences in practice patterns, health center capacities, mul-
tidisciplinary approaches in decision making, and system-
related variables such as time from diagnosis to medical
oncologist referral or to surgeon referral. When lung cancer
has been indirectly compared with breast cancer, evaluated in
a separate study,10 median waiting time from detection to
surgery was 107 and 36 days, respectively. Interestingly, the
range was amazingly large from 1 day to 3 years and a half
for lung cancer. A possible explanation of such wide patterns
of elapsed time could be due to the subset of patients who
underwent a period of monitoring of SAs before surgery. One
can suggest that when analyzing timelines in the lung cancer
management, it is very difficult to distinguish between dis-
ease driven timelines (solitary nodule requiring monitoring
before decision making and lack of specificity of some
symptoms as mentioned previously) and true wait times
reflective of system efficiency.
Implementation of new health systems have been de-
signed in an attempt at decreasing the time from suspicion
until diagnosis. In the November 2007 issue of the journal,
the Toronto group have reported an interesting “time to treat
program.”4 The tools used in this program were quite simple:
(i) a referral form that was uniformly applied to a single-entry
point of contact, (ii) a navigator, i.e., a person in an original
clerical position able to collect referral forms, facilitating
investigations and appointments with surgeon and/or medical
oncologist, and (iii) a clear diagnostic algorithm. This
“Time to treat” program was very efficient inasmuch as on
a 430 patient population-based evaluation of pre- and
post-implementation of the program, the time from suspi-
cion until referral for treatment decision has been reduced
from 128 to 20 days.
In the herein Netherlands study, 114 patients benefited
from the “Fast track one-day lung schedule.”3 Among them,
96 patients were finally diagnosed with malignancies includ-
ing lung cancer histology in 84. The specificity of the process
was 56%, with inflammatory diseases as the main reason for
false-positive diagnoses. Therefore, there might be some
troubles with reporting to the patient a conclusion of malig-
nancy, insofar as, at this step of the diagnosis process, there
was still no pathologic confirmation (which could not always
been given in 1 day). The authors have concluded that the
“fast track one-day lung schedule” can be useful, with a high
sensitivity and positive predictive value. Nevertheless, one
can stress the fact that negative predictive value was 77%
only. Therefore, there is another psychologic risk by report-
ing a diagnosis of benign disease at the end of the day and
afterward having to correct this into a diagnosis of malig-
nancy. The authors have stated that “delays in diagnosis and
treatment contribute to emotional distress.” It is true that
waiting such a diagnosis contribute to psychologic morbidity
for the patient and her (his) relatives. Nevertheless, one can
suggest that bringing to him a diagnosis at the end of a day
might be too fast, particularly in the case this could be a
false-positive or false-negative answer. The high-sensitivity
and positive predictive value (97% and 92%, respectively)
might result from a selection bias; as a reference, cancer
institute probably receives patients with SA (referred to the
Netherlands Antioni Van Leeuwenhoek Hospital) strongly
suggestive of malignancies. As a comparison, the results from
the prospective cohort study nested in the NCIs Prostate Lung
Colorectal Ovarian Cancer Screening Trial detected chest
radiographic abnormalities in 12,314 of 77,465 asymptomatic
individuals. Among these individuals, 232 (1.9%) had lung
cancer. The high sensitivity, as observed in the study by
Aukema et al., very likely reflects selection of symptomatic
patients. In such a selected population, the prevalence of
malignancy is high. Therefore, the positive predictive value
in their study might have been overestimated.3
Whether or not reducing the elapsed time from detec-
tion to diagnosis will significantly reduce the loss of chance
for a patient to be operated on remains controversial. In their
study, the authors suggested that a high percentage of the
accrual population of patients have been treated with curative
intent. Nevertheless, almost half of the patients achieved a
chemoradiotherapy program usually restricted to patients pre-
senting with a locally advanced stage, and only 30% of the
patients underwent surgery. This proportion does not seem to
be clearly superior to the one usually observed with standard
diagnosis procedures.3
In conclusion, interventions attempting to reduce the
elapsed time to treatment could not control the whole time-
lines but only the time from detection of the SA until
treatment by speeding up the diagnostic processes. We con-
gratulate the authors in their effort at modifying variables that
are specific to the health system efficiency. Nevertheless,
neither psychologic variables nor disease driven timelines
could be impacted by such intervention. This article by
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Aukema et al. is an attempt at reducing the wait times by
intervening in the system efficiency. Proof of efficacy will
warrant further study in a larger population comparing this
approach with more conventional ones.
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